By Puyaan Singh and Michael Erman Dec 16 (Reuters) - Pfizer said on Tuesday the next few years will be bumpy, beginning with ...

Today, Dec. 16, 2025, Pfizer's shrinking COVID cash flows could mean little growth next year as M&A bets will take time to ...

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Commissioner Marty Makary on Monday denied recent reports suggesting plans for his agency to add a black box warning onto ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and ...

The FDA contacted J&J right after ASH to discuss using a special fast pass on a multiple myeloma regimen. Elsewhere, a new ...

Now in 2025, the TGA has registered Pfizer's LP.8.1 vaccine, designed specifically to target the spike protein of LP.8.1.

The COVID-19 vaccines developed for the 2024-2025 respiratory disease season were around 75% effective at preventing ...

Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives ...

Pfizer shares fell after the company issued weaker-than-expected 2026 guidance, citing lower demand for COVID-19 products and ...

Built into the 2026 guidance is a $1.5 billion decline in sales of its COVID products—from an estimated $6.5 billion this ...

Dec 16 (Reuters) - Pfizer ‌on ​Tuesday ‌forecast 2026 profit below ​Wall Street estimates as ‍it expects lower ​sales of ​its ...